Timothy Rolph - 06 Oct 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Scientific Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 06 Oct 2022
Net transactions value: -$673,125
Form type: 4
Filing time: 07 Oct 2022, 18:00:28 UTC
Previous filing: 04 Oct 2022
Next filing: 27 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$210,900	+10,000	+5%	$21.09	208,837	06 Oct 2022	Direct	F1
transaction	AKRO	Common Stock	Sale	$884,025	-22,500	-11%	$39.29	186,337	06 Oct 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-14%	$0.000000	61,328	06 Oct 2022	Common Stock	10,000	$21.09	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3	This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 13, 2019.